Mission

View Point Medical is developing the only bio absorbable, injectable, fiducial tissue marker that is intra-operatively visible with both ultrasound and the naked eye

What We Do

View Point Medical is an early stage company pioneering fundamentally new localization technologies to improve cancer tumor resection and its management. View Point’s Signal Mark technology fills a direct need in localization that is key to successful biopsy, surgery and oncology

About

View Point Medical is developing bio absorbable markers and delivery devices to allow radiologist, surgeons and oncologists to visualize marked biopsy sights with ultrasound and the naked eye.

The technology is unique in its ability to improve historical marker limitations and enable a shared experience across the continuum of multidisciplinary care.

The company is pre FDA clearance and is working on Lung and Breast marker solutions under the brand name Signal Mark technology.

People

  • Jeffrey L. Port, M.D.

     Co-Founder

    Dr. Port is a Professor of Cardiothoracic Surgery and an Attending Surgeon in the Division of Thoracic Surgery at New York Presbyterian-Weill Cornell Medical Center within the Department of Cardiothoracic Surgery.  Dr. Port specializes in lung and esophageal cancers, mediastinal tumors and Barrett’s Esophagus. He also specializes in the area of minimally invasive thorascopic pulmonary surgery and the treatment of emphysema patients who require lung volume reduction. Dr. Port has authored numerous journals and book chapters on immunotherapy for the treatment of lung and esophageal cancer, as well as the development of vaccines. Dr. Port has an ongoing research collaboration with Dr. Rafii in the area of tumor endothelium and lung regeneration. He is a member of the American College of Surgeons, American Society of Clinical Oncology, American Association for Cancer Research, American Association of Thoracic Surgery, and Society for Thoracic Surgeons. Dr. Port is Board Certified in Surgery and Thoracic Surgery. He is also the founder of RF Surgical Systems, Inc., a medical device patient safety company which sold to Medtronic in 2015.

  • Bill Blair

  •  Co-Founder

    Bill Blair is the acting CTO of View Point Medical Inc. Previously Mr. Blair was a co-founder of RF Surgical Systems Inc. and served as the company’s Chief Technical Officer from 2005 until its sale to Medtronic in 2015. As an electrical by training, Mr. Blair has also held technology management and leadership roles with Bell Atlantic as well as several other innovative technology startup ventures. Among these are Telepad which pioneered early tablet computing, CBM to develop peer to peer private internet pipes, Advanced Modular Solutions which focused on small form factor clients, and FireTalk which focused on VOIP and SS7 signaling. Mr. Blair has patents in tablet computing, telecommunications, medical applications for communication systems, RFID and Antennas.  A passionate patient safety advocate, Mr. Blair utilizes his talents to create innovative technologies to advance the emerging digital patient safety space industry. Mr. Blair holds a B.S. degree in Electrical Engineering and Applied Physics with a minor in Economics from Case Western Reserve University.

     

  • John Merritt | LinkedIn
    John Merritt

     

  • John Merritt

  •  VP of Operations and Development

    John is the VP or operations and development of View Point Medical Inc. Previously Mr. Merritt  was a VP or operations at RF Surgical Systems Inc. and served until its sale to Medtronic and shortly into 2016. Prior John was Sr. Director of Advanced Engineering at CR Bard. John has developed numerous medical products in the biopsy, catheter and women’s healthcare space.

     

  • Mike Jones , B.S. M.S.

  • Principal Engineer

    Mr. Jones is the lead developer for  View Point Medical. He remains active as as previous co-founder of Salt Creek Medical since 2006. Prior Mr.Jones was a founder of Vascular Control Systems. He has developed products for a wide range of companies including SenoRX, MicroTheraputics, Applied Medical, Laparomed, and Mentor. He is named in over 40 pending and issued patents. and serves as director for Sensory Medical.  Mr. Jones holds a M.S. degree in Engineering Mechanics and Materials from California State University, Long Beach and a B.S. degree in Chemical Engineering from University of California Berkeley.

Board & Advisors

 

  • Dr. Gary Pace
    Board or Directors

Gary serves as Executive Director of View Point Medical. Gary is a seasoned biopharmaceutical executive with over 30 years of experience in the industry. He has co-founded a number of early stage life science companies, where he built products from the laboratory to commercialization.

Dr. Pace was Director of QRxPharma Ltd (ASX: QRX) from 2001 through 2014. He is currently a Director of ResMed Inc. (NYSE: RMD) and Transition Therapeutics Inc (TSX: TTH). He is an elected Fellow of the Australian Academy of Technological Sciences and Engineering, as well as author and co-author of over 50 research papers, reviews and patents. In 2003, Dr. Pace was awarded a Centenary Medal by the Australian Government for service to Australian society in research and development. Dr. Pace holds a Bachelor of Science (Honors) from the University of New South Wales and a PhD from MIT, where he was a Fulbright Scholar.

 

  • Josh Baltzell
    Board or Directors

Josh serves as an independent director of View Point Medical.  Josh is a Venture Partner at Split Rock Partners, and also serves as a Venture Partner at SightLine Partners. He has been with Split Rock since 2004 and with SightLine since 2014. Mr. Baltzell has over 20 years of experience in the healthcare industry.

Prior to his tenure in the venture capital industry, Josh held roles as an investment banker at Piper Jaffray Companies from 2000 to 2002, where he focused primarily on mergers and acquisitions in the medical device sector as well as various marketing and business development positions with SCIMED and Boston Scientific. Josh currently serves on the boards of Colorescience, EBR Systems, Inc., Entellus Medical (NASDAQ: ENTL),  Histogenics Corporation (NASDAQ: HSGX) and Magnolia Medical.  Josh is also a co-inventor of the DentaDish.

Josh’s previous investments and board affiliations have resulted in several M&A transactions including Ardian (Medtronic), Dfine (Merit Medical), RF Surgical (Medtronic), Skinmedica (Allergan) and Tarsus (Integra Lifesciences).

Josh holds a B.A. in Economics from St. Olaf College and an M.B.A. from the University of Minnesota’s Carlson School of Management.

 

  • Andrew C. Kummel

Science Adviser

Professor in the Department of Chemistry and BioChemistry at the UCSD, an affiliated faculty member in NanoEngineering and the Assistant Director of the UCSD Moores Cancer Center for Engineering and Physical Sciences. He is the author of over 190 papers on the topics of  nanoshell synthesis, nanoshells based imaging, automated detection of cancer, semiconductor chemistry, semiconductor device processing, ultramicroscopy, tumor ultrasound imaging and ablation.

 

  • Professor William Trogler

Science Adviser

Professor in the Department of Chemistry and Biochemistry at UCSD, an affiliated faculty member in NanoEngineering and a member of the UCSD Moores Cancer Center
He is the author of over 200 papers on inorganic chemistry, including nanoshell materials synthesis, photochemistry, reaction mechanisms, catalysis, fluorescent sensing of explosives and toxicants, spectroscopy, environmental chemistry, electrochemistry, organometallic and transition metal chemistry

Contact